Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings

References

• HoggRLimaVSterneJAAntiretroviral Therapy Cohort CollaborationLife expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studiesLancet2008372963529329918657708
   PubMed Web of Science ®Google Scholar
• MillsEBakandaCChanKfor the TASO-CAN groupLife expectancy of individuals on combination antiretroviral therapy in Uganda: a cohort analysis of more than 23,000 patientsAbstract TUPE0212, presented at the XVIII International AIDS ConferenceJuly 18–23, 2010Vienna, Austria
   Google Scholar
• MillsEJNachegaJBBangsbergDRAdherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitatorsPLoS Med2006311e43817121449
   PubMed Web of Science ®Google Scholar
• FordNMofensonLKranzerKSafety of efavirenz in first-trimester of pregnancy: A systematic review and meta-analysis of outcomes from observational cohortsAIDS201024101461147020479637
   PubMed Web of Science ®Google Scholar
• GarveyLWinstonARilpivirine: A novel non-nucleoside reverse transcriptase inhibitorExpert Opin Investig Drugs200918710351041
   PubMed Web of Science ®Google Scholar
• AdamsJPatelNMankaryousNTadrosMMillerCDNonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agentsAnn Pharmacother201044115716519996323
   PubMed Web of Science ®Google Scholar
• HughesCARobinsonLTsengAMacArthurRDNew antiretroviral drugs: A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravirExpert Opin Pharmacother20091015244266
   Web of Science ®Google Scholar
• MillerCDCrainJTranBPatelNRilpivirine: A new addition to the anti-HIV-1 armamentariumDrugs Today (Barc)201147151521373646
   PubMed Web of Science ®Google Scholar
• GoebelFYakovlevAPozniakALShort-term antiviral activity of TMC278 – a novel NNRTI – in treatment-naive HIV-1-infected subjectsAIDS200620131721172616931936
   PubMed Web of Science ®Google Scholar
• ArastéhKRiegerAYeniPShort-term randomized proof-of- principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapyAntiviral Ther2009145713722
   PubMed Web of Science ®Google Scholar
• PozniakALMorales-RamirezJKatabiraEEfficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: Week 96 results of a phase IIb randomized trialAIDS2010241556519926964
   PubMed Web of Science ®Google Scholar
• Van’t KloosterGHoebenEBorghysHPharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulationAntimicrob Agents Chemother20105452042205020160045
   PubMed Web of Science ®Google Scholar
• BaertLvan’t KloosterGDriesWDevelopment of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatmentEur J Pharm Biopharm200972350250819328850
   PubMed Web of Science ®Google Scholar
• Van GyseghemEPendelaMBaertLPowder for reconstitution of the anti-HIV-1 drug TMC278 – formulation development, stability and animal studiesEur J Pharm Biopharm200870385386018657611
   PubMed Web of Science ®Google Scholar
• CohenCMolinaJMCahnPPooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patientsAbstract 048, presented at the Tenth International Congress on Drug Therapy in HIV InfectionNovember 7–11, 2010Glasgow, Scotland
   Google Scholar
• RimskyLEronJClotetBCharacterization of the resistance profile of TMC278: 48-week analysis of the phase 3 studies ECHO and THRIVEAbstract H-1810, presented at the 50th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 12–15, 2010Boston, MA
   Google Scholar
• VerloesRvan’t KloosterGBaertLTMC278 long acting – a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteersAbstract TUPE0042, presented at the XVII International AIDS ConferenceAugust 3–8, 2008Mexico City, MX
   Google Scholar
• CrauwelsHvan HeeswijkRKestensDThe pharmacokinetic (PK) interaction between rifabutin and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)Abstract TUPE0080, presented at the XVIIth International AIDS ConferenceAugust 3–8, 2008Mexico City, MX
   Google Scholar
• CrauwelsHvan HeeswijkRMcNeeleyDRelative bioavailability of a concept paediatric formulation of TMC278, an investigational NNRTIAbstract TUPE0158, presented at the XVIIIth International AIDS ConferenceJuly 18–23, 2010Vienna, Austria
   Google Scholar
• HoetelmansRKestensDMarienKEffect of food and multiple dose pharmacokinetics of TMC278 as an oral tablet formulation Abstract TuPe31B10presented at the Third International AIDS Society Conference on HIV Pathogenesis and TreatmentJuly 24–27, 2005Rio de Janeiro, Brazil
   Google Scholar
• De BéthuneM-PAndriesKAzijinHTMC278, a new potent NNRTI, with an increased barrier to resistance and favourable pharmacokinetic profilePoster 556, presented at the 12th Conference on Retroviruses and Opportunistic InfectionsFebruary 22–25, 2005Boston, MA
   Google Scholar
• Van HeeswijkRHoetelmansRMWKestensDThe effects of CYP3A4 modulation on the pharmacokinetics of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)Poster 74, presented at the Seventh International Workshop of Clinical PharmacologyApril 20–22, 2006Lisbon, Portugal
   Google Scholar
• ChamieGLuetkemeyerACharleboisEHavlirDVTuberculosis as part of the natural history of HIV infection in developing countriesClin Infect Dis15;50Suppl 3S245254
   Google Scholar
• Van HeeswijkRHoetelmansRMWKestensDThe pharmacokinetic interaction between TMC 278, a next generation NNRTI, and once-daily darunavir/ritonavir in HIV negative volunteersPresented at the 47th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 17–20, 2007Chicago, IL
   Google Scholar
• CrauwelsHvan HeeswijkRVandevoordeAPharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadoneAbstract WEPE0089, presented at the XVIII International AIDS ConferenceJuly 18–23, 2010Vienna, Austria
   Google Scholar
• Van HeeswijkRPGHoetelmansRMWAharchiFThe pharmacokinetic interaction between atorvastatin and TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor, in HIV-negative volunteersPresented at the 11th European AIDS ConferenceOctober 24–27, 2007Madrid, Spain
   Google Scholar
• CrauwelsHvan HeeswijkRCornelisLPharmacokinetic interaction study between TMC278, an NNRTI, and the contraceptives norethindrone plus ethinylestradiolPresented at the 12th European AIDS ConferenceNovember 11–14, 2009Cologne, Germany
   Google Scholar
• CrauwelsHvan HeeswijkRStevensMTMC278, a next-generation NNRTI, does not alter the pharmacokinetics of sildenafilAbstract presented at the 10th International Workshop on Clinical Pharmacology of HIVApril 15–17, 2009Amsterdam, the Netherlands
   Google Scholar
• SantoscoyMCahnPGonsalezCTMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naïve patients: 96-week results of study C204Abstract TUAB0103, presented at the XVIIth International Aids ConferenceAugust 3–8, 2008Mexico City, MX
   Google Scholar
• MathiasAMMWeiXDaveABioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DFAbstract LBPE17, presented at the XVIII International AIDS ConferenceJuly 18–23, 2010Vienna, Austria
   Google Scholar
• JanssenPALewiPJArnoldEIn search of a novel anti-HIV drug: Multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)J Med Chem20054861901190915771434
   PubMed Web of Science ®Google Scholar
• CrauwelsHMvan HeeswijkRBollenAThe effect of different types of food on the bioavailability of TMC278, an investigational NNRTIPoster presented at the Ninth International Workshop on Pharmacology of HIV TherapyApril 7–9, 2008New Orleans, LA
   Google Scholar
• HoetelmansRKestensDStevensMPharmacokinetic interaction between the novel non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 and tenofovir fumarate (TDF) in healthy volunteersPoster 18, presented at the Sixth International Workshop on Clinical Pharmacology of HIV TherapyApril 28–30, 2005Quebec City, QC
   Google Scholar
• Van HeeswijkRHoetelmansRMKestensDThe pharmacokinetic interaction between ketoconazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in healthy HIV-negative subjectsAbstract TUPE0087, presented at the XVI International AIDS ConferenceAugust 13–18, 2006Toronto, ON
   Google Scholar
• Van HeswijkRHoetelmansRMKestensDThe pharmacokinetic (PK) interaction between famotidine and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI), in HIV-negative volunteersAbstract TUPDB01, presented at the Fourth International AIDS Society Conference on HIV PathogenesisJuly 22–25, 2007Sydney, Australia
   Google Scholar
• VanveggelSBuelensACrauwelsHTMC278 25 mg qd has no effect on corrected QT interval in a study in HIV-negative volunteersAbstract PE7.1/2, presented at the 12th European AIDS ConferenceNovember 11–14, 2009Cologne, Germany
   Google Scholar
• DesmidtMWillemsBDomPAbsence of a teratogenic potential from a novel next generation NNRTI, TMC278Abstract PE7.1/4 presented at 12th European AIDS ConferenceNovember 11–14, 2009Cologne, Germany
   Google Scholar
• PinheiroEVasanAKimJYExamining the production costs of antiretroviral drugsAIDS200620131745175216931939
   PubMed Web of Science ®Google Scholar
• Campaign for Essential MedicinesUntangling the Web of Antiretroviral Price Reduction13th edGeneva, SwitzerlandMedecins Sans Frontieres2010 Available at: http://utw.msfaccess.org/background/aids_progress_under_siegeAccessed March 4, 2011
   Google Scholar
• Johnson & JohnsonTibotec signs multiple agreements with generic manufacturers to provide access to new HIV treatment Available at: http://www.jnj.com/connect/news/all/Tibotec-Signs-Multiple-Agreements-with-Generic-Manufacturers-to-Provide-Access-to-New-HIV-TreatmentAccessed March 30, 2011
   Google Scholar
• World Health OrganizationTowards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress reportGeneva, SwitzerlandWHO/UNAIDS/UNICEF2009
   Google Scholar
• World Health OrganizationUpdated List of Missing Drug Formulations for HIV Treatment to be Reviewed by the WHO 18th Expert Committee on the Selection and Use of Essential Medicines Available at: http://www.who.int/selection_medicines/committees/expert/18/policy/Missing_HIV_formulations.pdfAccessed March 30, 2011
   Google Scholar
• GrantRMLamaJRAndersonPLPreexposure chemoprophylaxis for HIV prevention in men who have sex with menN Engl J Med2010363272587259921091279
   PubMed Web of Science ®Google Scholar
• GrohskopfLGvetadzeRPathakSPreliminary analysis of bio-medical data from the Phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among US men who have sex with men (MSM)Abstract FRLBC102, presented at the XVIII International AIDS ConferenceJuly 18–23, 2010Vienna, Austria
   Google Scholar
• Abdool KarimQAbdool KarimSSFrohlichJAEffectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in womenScience201032959961168117420643915
   PubMed Web of Science ®Google Scholar
• GostinLOKimSCEthical allocation of preexposure HIV prophylaxisJAMA2011305219119221224461
   PubMed Web of Science ®Google Scholar